According to Sarepta Therapeutics 's latest financial reports the company's current earnings (TTM) are -$0.53 B. In 2022 the company made an earning of -$0.69 B a decrease over its 2021 earnings that were of -$0.42 B.The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -$0.53 B | -24.62% |
2022 | -$0.69 B | 64.69% |
2021 | -$0.42 B | -24.25% |
2020 | -$0.56 B | -22.53% |
2019 | -$0.72 B | 96.87% |
2018 | -$0.37 B | 645.68% |
2017 | -$48.63 M | -81.81% |
2016 | -$0.27 B | 21.47% |
2015 | -$0.23 B | 62.04% |
2014 | -$0.14 B | 21.26% |
2013 | -$0.12 B | 60.93% |
2012 | -$69.59 M | 93.69% |
2011 | -$35.93 M | 71.58% |
2010 | -$20.94 M | 35.06% |
2009 | -$15.51 M | -11.62% |
2008 | -$17.55 M | -47.02% |
2007 | -$33.11 M | 0.38% |
2006 | -$32.99 M | 88.3% |
2005 | -$17.52 M | -30.06% |
2004 | -$25.05 M | 32.69% |
2003 | -$18.88 M | -25.52% |
2002 | -$25.35 M | 64.52% |
2001 | -$15.41 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Gilead Sciences GILD | $6.85 B | -1,418.79% | ๐บ๐ธ USA |
PTC Therapeutics
PTCT | -$0.7 B | 33.84% | ๐บ๐ธ USA |
Novavax NVAX | -$0.53 B | 1.64% | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | -$0.32 B | -39.95% | ๐บ๐ธ USA |
Insmed INSM | -$0.68 B | 28.97% | ๐บ๐ธ USA |
BioCryst Pharmaceuticals
BCRX | -$0.23 B | -56.50% | ๐บ๐ธ USA |
Avidity Biosciences RNA | -$0.22 B | -59.20% | ๐บ๐ธ USA |